Novartis Ag

Novartis Pharma Gmbh

Leslie Wighton McQuire

John Henry Van Duzer

Benjamin B Mugrage

Ruben Alberto Tommasi

Roger A Fujimoto

Michael David Shultz

Olivier Rogel

Claus Ehrhardt

Pascal Rigollier

Qi-Ying Hu

Christopher Michael Adams

Julien Papillon

Daqiang Xu

Paul David Greenspan

Scott Douglas Cowen

Mahavir Prashad

David Thomas Parker

Sven Weiler

Lauren Gilchrist Monovich

Sompong Wattanasin

Eva Altmann

Claudia Betschart

Junichi Sakaki

Rene Lattmann

Martin Missbach

Naoki Teno

Leslie Ann Robinson

John H VanDuzer

Michihiro Takai

Miyuki Horiuchi

Keigo Gohda

Roger Aki Fujimoto

Jerry W Skiles

Philippe Nantermet

The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

ArylSulfonamide-based matrix metalloprotease inhibitors

The present invention provides novel organic compounds of Formula (I): methods of use, and pharmaceutical compositions thereof. 

Organic compounds

Arylsulfonamide based matrix metalloprotease inhibitors

The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors

Arylsulfonamide-based matrix metalloprotease inhibitors

The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.

Certain phenylacetic acids and derivatives

Disclosed are the compounds of formula I wherein R is methyl or ethyl; Ris chloro or fluoro; Ris hydrogen or fluoro; Ris hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; Ris hydrogen or fluoro; and Ris chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.

Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Compounds of the formula (I), wherein R is aryl or biaryl; R is aryl-lower alkyl, biaryl-lower alkyl, benzo-fused cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C -C -alkyl in which C -C -alkyl is interrupted by Y; Y is O, S, SO, SO , CO or NR ; R is hydrogen or lower alkyl; or R and R combined are C -C -alkylene or C -C -alkylene interrupted by Y; R is hydrogen or lower alkyl; R is hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, biaryl-lower alkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C -C -alkyl in which C -C -alkyl is interrupted by Y; R is hydrogen, lower alkyl or aryl-lower alkyl; and pharmaceutically acceptable salts thereof, which are useful as cysteine cathepsin inhibitors

N-substituted peptidyl nitriles as cysteine cathepsin inhibitors

Dipeptide nitriles

Growing community of inventors

Warren, NJ, United States of America

Leslie Wighton McQuire